Case Report
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 18, 2017; 9(11): 562-566
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.562
18-Fluoro-deoxyglucose uptake in inflammatory hepatic adenoma: A case report
Willy Liu, Jean Delwaide, Noella Bletard, Philippe Delvenne, Paul Meunier, Roland Hustinx, Olivier Detry
Willy Liu, Olivier Detry, Department of Abdominal Surgery and Transplantation, CHU Liege (CHU-ULg), B4000 Liege, Belgium
Jean Delwaide, Department of Hepato-gastroenterology, CHU Liege (CHU-ULg), B4000 Liege, Belgium
Noella Bletard, Philippe Delvenne, Department of Pathology, CHU Liege (CHU-ULg), B4000 Liege, Belgium
Paul Meunier, Department of Radiology, CHU Liege (CHU-ULg), B4000 Liege, Belgium
Roland Hustinx, Department of Nuclear Imaging, CHU Liege (CHU-ULg), B4000 Liege, Belgium
Author contributions: Liu W collected the data, performed the literature review and wrote the paper; Delwaide J took care of the patient and collected the data; Bletard N and Delvenne P performed the pathology analyses and figures; Meunier P performed the radiologic investigations; Hustinx R performed the PET-CTs and wrote the manuscript; Detry O followed and operated the patients on and wrote the manuscript.
Institutional review board statement: According to the Belgian Law and medical ethics, there is no need for an institutional review board for a retrospective report of an anonymized patient’s case.
Informed consent statement: According to the Belgian Law and medical ethics, there is no need for a consent form for the retrospective report of an anonymized patient’s case.
Conflict-of-interest statement: The authors have no conflict-of-interest to disclose concerning this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Olivier Detry, Professor, Department of Abdominal Surgery and Transplantation, CHU Liege (CHU-ULg), Sart Tilman B35, B4000 Liege, Belgium. oli.detry@chu.ulg.ac.be
Telephone: +32-4-3667645 Fax: +32-4-3667069
Received: August 28, 2016
Peer-review started: August 29, 2016
First decision: November 21, 2016
Revised: January 25, 2017
Accepted: March 21, 2017
Article in press: March 21, 2017
Published online: April 18, 2017
Processing time: 228 Days and 14.9 Hours
Core Tip

Core tip: In cancer therapy, the use of 18-Fluoro-deoxyglucose (18FDG) positron emission tomography computed tomography as a staging or prognostic tool, is increasing. This is also the case for primary or secondary liver cancer. In this paper, the authors report the first description of an inflammatory hepatic adenoma with 18FDG uptake.